Notice: Get a jump on 2015 — Pay your 2015 ASA membership dues now!

>

MEETINGS / EVENTS

RSS

January 23 - 25 2015, 12:00 AM - 12:00 AM

ASA PRACTICE MANAGEMENT 2015

February 07 - 08 2015, 12:00 AM - 12:00 AM

ASA Certificate in Business Administration 2015

June 26 - 28 2015, 12:00 AM - 12:00 AM

Annual Perioperative Surgical Home Summit

>

FDA MEDWATCH ALERTS

December 18, 2014

0.9 Percent Sodium Chloride Injection USP in 100 mL MINI-BAG PLUS Container by Baxter: Recall - Particulate Matter

Summary:

FDA MedWatch Recall - Particulate Matter

November 21, 2014

FDA MedWatch - Respironics California, Esprit V1000 and V200 Ventilators: Class I Recall - Power Failure May Occur

Summary:

FDA MedWatch Respironics California Esprit V1000 and V200 Ventilators Class I Recall

November 21, 2014

FDA MedWatch - Highly Concentrated Potassium Chloride Injection, 10 mEq per 100 mL by Baxter: Recall - Mislabeled

Summary:

Highly Concentrated Potassium Chloride Injection 10 mEq per 100 mL by Baxter Recall Mislabeled

>

ASA FEATURED PRODUCT

Add this product to your shopping cart

Self-Education and Evaluation (SEE) Program

SKU: 30701-14CE

... Read more »

Single Copies, Member Price: $360

FDA Removes Unapproved Prescription Drug Products Containing Codeine and Dihydrocodeine from the Market

Monday, January 13, 2014

The U.S. Food and Drug Administration (FDA) has ordered companies to stop manufacturing and distributing unapproved prescription drug products containing codeine and unapproved prescription drug products containing dihydrocodeine as of February 24, 2014 and April 10, 2014, respectively. 

The drugs covered by this action lack the required FDA approval and are:

  • single-ingredient codeine sulfate oral tablets;
  • single-ingredient codeine phosphate injections;
  • combination products containing codeine phosphate; and
  • combination products containing dihydrocodeine bitartrate.  

For historical reasons, some prescription drug products are available in the United States but lack FDA approval for marketing.  FDA is taking this action as part of the Agency’s continuing effort to ensure that prescription drugs marketed in the United States  have the required FDA approval, which means that they have been found to be safe, effective, of good quality, and are appropriately labeled. 

According to the FDA, the announced removal  is not a recall, and previously manufactured unapproved drug products affected by this action may still be found on pharmacy shelves for a short period of time (until the inventory has been depleted or until the products’ expiration date).

Read FDA’s Q&A on the removal of these products from the market.

« Back to FDA Alerts and Recalls